Conference
Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study.
Abstract
394
Background: Data regarding the benefits of FFX and GnP in patients (pts) with initially uLAPC is limited. FFX and GnP have been universally publicly funded for first-line uLAPC in Ontario, Canada, since April 2015. The aims of this study are to determine (1) the overall survival (OS) of pts receiving FFX and GnP, (2) the surgical conversion rate of FFX and GnP, and (3) whether resection is associated with better OS in pts …
Authors
Chan KK; Guo H; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S
Volume
35
Pagination
pp. 394-394
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2017
DOI
10.1200/jco.2017.35.4_suppl.394
Conference proceedings
Journal of Clinical Oncology
Issue
4_suppl
ISSN
0732-183X